The United States is preparing to accelerate access to innovative medical technologies by introducing a faster payment pathway for newly approved devices under Medicare, according to recent reports. The initiative—referred to as the “RAPID” coverage pathway—aims to significantly reduce the time between regulatory approval and reimbursement, a step that could transform how quickly patients benefit from cutting-edge treatments.
Currently, once a device receives clearance from the U.S. Food and Drug Administration, it can take more than a year for the Centers for Medicare & Medicaid Services to finalize coverage and payment decisions. This delay has been a long-standing concern in the healthcare industry, as it often slows patient access to new and potentially life-saving technologies. Under the proposed RAPID system, that waiting period could be reduced to approximately 60 to 90 days.
The program is expected to initially include around 40 breakthrough devices—innovations that offer meaningful improvements over existing treatments. These may include advanced heart devices, nerve stimulators, and other high-impact technologies designed to enhance patient outcomes and quality of life.
Experts believe the new pathway will improve coordination between regulatory and payment bodies, ensuring that approval and reimbursement processes run in parallel rather than sequentially. This change is also likely to support medical device manufacturers by speeding up market access and encouraging further innovation.
Overall, the move reflects a broader effort to modernize the healthcare system and remove administrative barriers. By reducing delays in reimbursement, the US government aims to ensure that patients, particularly Medicare beneficiaries, can access the latest medical advancements more quickly and efficiently.